Drug profile · INN
trastuzumab and hyaluronidase-oysk
HERCEPTIN HYLECTA
trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — trastuzumab and hyaluronidase-oysk
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is trastuzumab and hyaluronidase-oysk?
trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for trastuzumab and hyaluronidase-oysk?
HERCEPTIN HYLECTA is a marketed brand name for trastuzumab and hyaluronidase-oysk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trastuzumab and hyaluronidase-oysk?
trastuzumab and hyaluronidase-oysk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.